Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...
Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.
The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...
The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...
The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart), ...
19 小时
Interesting Engineering on MSNFDA approves first-ever rapid-acting insulin biosimilar for diabetes treatmentFirst-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control ...
Being a rapid-acting insulin, insulin-aspart-szjj helps to lower mealtime blood sugar spikes to improve control of blood sugar in diabetes patients. The approved indication for the biosimilar is for ...
Sanofi has received U.S. Food and Drug Administration (FDA) approval for Merilog (insulin-aspart-szjj), a biosimilar to ...
2 天
来自MSNFDA Approves Groundbreaking Rapid-Acting Insulin Biosimilar Merilog, Offering New Hope for ...The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果